Jamin D, Shulman I, Lam H T, Aguilar S, Shields M, Cohen J, Gill P, Levine A
University of Southern California School of Pharmacy, Los Angeles, 90033.
Arch Pathol Lab Med. 1988 Sep;112(9):898-900.
Drugs and chemicals containing multiple reactive carbonyl groups have been postulated to produce nonimmunologic positive direct antiglobulin tests (DATs) both in vitro and in vivo. Suramin sodium, a reverse transcriptase inhibitor that was under investigation as a potential treatment for human immunodeficiency virus infection, has six reactive carbonyl groups. Because of suramin's chemical structure, it was hypothesized that the drug might cause a positive DAT in vitro and possibly in vivo. Suramin was found to produce a positive DAT in vitro at concentrations of 2100 mg/L or greater but did not cause a positive DAT in five patients with acquired immunodeficiency syndrome who were treated with suramin, probably because the serum levels of suramin were too low in these patients (peak therapeutic blood levels ranged from 171 to 443 mg/L).
含有多个反应性羰基的药物和化学物质被推测在体外和体内均可产生非免疫性直接抗球蛋白试验（DAT）阳性结果。苏拉明钠是一种逆转录酶抑制剂，当时正作为人类免疫缺陷病毒感染的潜在治疗药物进行研究，它有六个反应性羰基。由于苏拉明的化学结构，推测该药物可能在体外以及可能在体内导致DAT阳性。研究发现，苏拉明在浓度为2100mg/L或更高时可在体外产生DAT阳性，但在接受苏拉明治疗的五名获得性免疫缺陷综合征患者中未导致DAT阳性，这可能是因为这些患者体内的苏拉明血清水平过低（治疗时的血药峰值水平在171至443mg/L之间）。
